[HTML][HTML] The impact of HPV multi-cohort vaccination: real-world evidence of faster control of HPV-related morbidity
M Orumaa, SK Kjaer, C Dehlendorff, C Munk, AO Olsen… - Vaccine, 2020 - Elsevier
Abstract Background In 2009, both Norway and Denmark initiated routine quadrivalent
human papillomavirus vaccination (qHPV) for 12-year-old girls; however, Denmark also …
human papillomavirus vaccination (qHPV) for 12-year-old girls; however, Denmark also …
Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study
A Söderlund-Strand, I Uhnoo, J Dillner - Cancer Epidemiology, Biomarkers & …, 2014 - AACR
Background: Organized human papillomavirus (HPV) vaccination was introduced in
Sweden in 2012. On-demand vaccination was in effect from 2006 to 2011. We followed the …
Sweden in 2012. On-demand vaccination was in effect from 2006 to 2011. We followed the …
Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550 000 young girls
M Blomberg, C Dehlendorff, C Sand… - Clinical Infectious …, 2015 - academic.oup.com
Background. Reducing the number of doses in the human papillomavirus (HPV) vaccination
regimen from 3 to 2 could increase coverage rates. In this cohort study, we assessed the risk …
regimen from 3 to 2 could increase coverage rates. In this cohort study, we assessed the risk …
[HTML][HTML] Risk of genital warts in renal transplant recipients—A registry-based, prospective cohort study
HK Larsen, LT Thomsen, M Haedersdal… - American Journal of …, 2019 - Elsevier
Genital warts (GWs) are a risk factor for subsequent human papillomavirus (HPV)–related
anogenital cancers. In this register-based, prospective cohort study, we estimated the risk of …
anogenital cancers. In this register-based, prospective cohort study, we estimated the risk of …
Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent …
V Gilca, C Sauvageau, G Panicker, G De Serres… - Vaccine, 2018 - Elsevier
Background Limited data is available on the use of different HPV vaccines in the same
subjects. We evaluated the immunogenicity and safety of a mixed vaccination schedule with …
subjects. We evaluated the immunogenicity and safety of a mixed vaccination schedule with …
Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions
C Dehlendorff, P Sparén, B Baldur-Felskov… - Vaccine, 2018 - Elsevier
Background Based on immunogenicity studies, a 2 dose HPV vaccination-schedule was
recently recommended for girls younger than 15 years. We aimed to investigate the …
recently recommended for girls younger than 15 years. We aimed to investigate the …
9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV
P Pitisuttithum, C Velicer… - Expert Review of Vaccines, 2015 - Taylor & Francis
Human papillomavirus (HPV) is the causative agent of nearly all cervical cancer cases as
well as a substantial proportion of anal, vulvar, vaginal, penile and oropharyngeal cancers …
well as a substantial proportion of anal, vulvar, vaginal, penile and oropharyngeal cancers …
Factors impacting HPV vaccination: lessons for health care professionals
AM Hofstetter, SL Rosenthal - Expert review of vaccines, 2014 - Taylor & Francis
HPV infection leads to significant morbidity and mortality worldwide. The HPV vaccine is
currently licensed and recommended for adolescents and young adults in many countries …
currently licensed and recommended for adolescents and young adults in many countries …
One-dose human papillomavirus vaccination and the risk of genital warts: a Danish nationwide population-based study
L Baandrup, C Dehlendorff… - Clinical Infectious …, 2021 - academic.oup.com
Background Increasing evidence suggests that 1-dose human papillomavirus (HPV)
vaccination may protect significantly against HPV-related disease. We provide nationwide …
vaccination may protect significantly against HPV-related disease. We provide nationwide …
An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to …
P Kosalaraksa, J Mehlsen, T Vesikari… - The Pediatric …, 2015 - journals.lww.com
Background: A 9-valent human papillomavirus (9vHPV) vaccine has recently been reported
to be safe and highly efficacious against infection and disease related to …
to be safe and highly efficacious against infection and disease related to …